NOV 28, 2016 6:04 AM PST

Hepatitis C Sabotages the Immune System to Infect Human Cells

WRITTEN BY: Kara Marker
Hepatitis C virus protects itself from the immune system by blocking signals that trigger a response in liver cells. Scientists are working to prevent the virus from evading the immune system; hepatitis C is the most common cause of chronic hepatitis and the leading cause of liver cancer in the United States.
Hepatitis C is a contagious liver disease caused by a virus that ranges in severity from a mild illness lasting a few weeks to a serious, lifelong illness that attacks the liver. Source: Tech Times
Interferon-alpha drugs have long been used to treat chronic hepatitis C virus, sometimes in combination with an antiviral drug called ribavirin. However, for 60 percent of patients, the treatment fails, and a chronic hepatitis C infection runs rampant.

Interferons are released by virally-infected cells, serving as messengers to surrounding cells that a viral infection is nigh. Some interferons can trigger apoptosis in lost cells already infected to prevent the virus from reaching more healthy cells, and they are also responsible for mounting a larger immune response targeting the invader.

"The finding helps explain why many patients fail [to respond to] certain drug treatments, and should help develop more effective alternate treatment protocols," said corresponding author of recent University of Washington study, Ram Savan, PhD.

A previous study from Savan’s group looked at hepatitis C virus invading a liver cell. The virus takes over the use of the host cell’s cellular machinery, triggering the activation of two genes, MYH7 and MYH7B, that produce two microRNAs that interfere with the production of two interferons. They also found that the same microRNAs inhibit the production of a critical receptor for the interferon-driven antiviral immune response.

With a dual, virus-driven attack on interferon production, hepatitis C-infected cells are left virtually defenseless and unable to warn their peers of an imminent attack.

"This may in part explain why interferon treatments, which harness a type I interferon, fail in so many patients," said lead author and current graduate student Abigail Jarret.

Jarret’s current study was published recently in the journal Nature Medicine.
 


Source: University of Washington Health Sciences/UW Medicine
 
About the Author
Master's (MA/MS/Other)
I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
Loading Comments...